U.S. Food and Drug Administration
Protecting and Promoting Your Health
Examples of type B meetings include:
- Pre-investigational new drug application (pre-IND) meetings
- Certain end-of-phase 1 meetings for Subpart E or Subpart H or similar products
- End-of-phase 2 and pre-phase 3 meetings
- Pre-new drug application (pre-NDA) pre-biologics license application (pre-BLA) meetings
- Meetings regarding risk evaluation and mitigation strategies (REMS) or post-marketing requirements that occur outside the context of the review of a marketing application
- Post-action meetings requested by the sponsor 3 months or more after an FDA regulatory action other than an approval
- Meetings held to discuss the overall development program for products granted Breakthrough Therapy designation status.

|
Ask the FDA
for more information
|
Click the FDA Representative to learn more. Click NEXT to continue.